What is the 13F Pro Quality Score for ARDX?

13F Pro ranks ARDELYX, INC. (ARDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARDX's current score at https://13fpro.ai/company/ARDX (free sign-up required for the full ranking).

Which hedge funds own the most ARDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ARDX include BlackRock,, Rubric Capital Management, MILLENNIUM MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ARDX as soon as new 13F filings post.

Where does 13F Pro source ARDX data?

All ARDELYX, INC. fundamentals and ownership data come directly from SEC EDGAR. ARDELYX, INC. files with the SEC under CIK 1437402. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARDX in?

ARDELYX, INC. (ARDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARDX research updated on 13F Pro?

ARDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ARDELYX, INC.(ARDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1437402 ARDX stock profile & AI dashboard →

13F Pro Quality Score

41.9/100

Rank #2,039 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

93.9/100

Profitability

21.6/100

Balance Sheet

16.6/100

Earnings Quality

40.5/100

Free Cash Flow

21.2/100

Institutional Flow

59.7/100

Revenue Scale

35.2/100

Dilution Risk

14.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ARDX Scores 42/100

exact factor attribution · 2026-09-11

ARDX's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.8 pts

94th pct

Institutional flow

+0.5 pts

60th pct

Earnings growth

-0.5 pts

40th pct

Earnings quality

-0.9 pts

41th pct

Shareholder dilution

-1.8 pts

14th pct

Scale

-2.2 pts

35th pct

Capital efficiency

-3.3 pts

17th pct

Profitability

-4.3 pts

22th pct

Free cash flow

-4.3 pts

21th pct

Latest change (2026-08-06): 35 → 39 · ↑ Free cash flow 12→26; ↑ Profit margin 13→23; despite ↓ Revenue growth 94→83

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ARDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ARDELYX, INC. (ARDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARDX at 41.9/100 on a 32-signal composite quality model, placing it at rank #2,039 of 2,962 stocks — the bottom half of the AI-ranked universe. ARDX scores in the top quartile across revenue growth (93.9). Areas of concern include balance sheet strength (16.6) and free cash flow (21.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARDELYX, INC. reports quarterly revenue of $120.9M, net income of $-16.7M, an operating margin of -10.3%. Top institutional holders of ARDX by reported 13-F value include BlackRock, Rubric Capital Management, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. ARDX trades on the Nasdaq exchange and files with the SEC under CIK 1437402. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARDELYX, INC. directly from SEC EDGAR. ARDELYX, INC.'s 13F Pro composite quality score has ranged between 9 and 42 since 2021, currently 41.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ARDELYX, INC.

Quirks, history, and lore behind ARDX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on gastrointestinal and cardiorenal diseases.
2
The Numbers
Revenue in the range of tens of millions of dollars annually — classic early-commercial-stage biotech — with a market cap that has swung wildly on FDA decisions.
3
The History
Founded in the early 2000s, the company spent over a decade developing drugs that work right inside the gut lining, targeting ion transporters rather than the usual molecular suspects.
4
The Secret
Its science centers on blocking a specific sodium-hydrogen exchanger in the intestine — a mechanism most pharma companies completely ignored — to manage chronic kidney disease complications.
5
The Lore
Its lead approved drug, tenapanor, treats hyperphosphatemia in dialysis patients — a mouthful of a condition that affects millions and had very few good options.
6
The Giveaway
Ticker ARDX, drug named XPHOZAH — if you know that tenapanor finally won FDA approval after a bumpy road, you've been watching this kidney-focused biotech very closely.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$120.9M

Net Income

Q2 2026

$-16.7M

Free Cash Flow

Q2 2026

$-6.4M

Operating Margin

Q2 2026

-10.3%

ROIC

Q2 2026

-12.4%

D/E Ratio

Q2 2026

1.69

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+22.1% YoY

$407.3MFY 2025

FY22 $52.2MFY23 $124.5MFY24 $333.6MFY25 $407.3M

Net Income

-57.4% YoY

$-61.6MFY 2025

FY22 $-67.2MFY23 $-66.1MFY24 $-39.1MFY25 $-61.6M

Operating Income

-46.6% YoY

$-41.0MFY 2025

FY22 $-63.8MFY23 $-63.3MFY24 $-27.9MFY25 $-41.0M

EPS (Diluted)

-52.9% YoY

$-0.26FY 2025

FY22 $-0.42FY23 $-0.30FY24 $-0.17FY25 $-0.26

Total Assets

+15.1% YoY

$501.6MFY 2025

FY22 $190.1MFY23 $297.6MFY24 $435.8MFY25 $501.6M

Total Debt

+34.5% YoY

$202.8MFY 2025

FY22 $26.7MFY23 $49.8MFY24 $150.9MFY25 $202.8M

Op. Cash Flow

+5.2% YoY

$-42.5MFY 2025

FY22 $-70.0MFY23 $-89.7MFY24 $-44.8MFY25 $-42.5M

Free Cash Flow

+4.0% YoY

$-44.0MFY 2025

FY22 $-70.1MFY23 $-90.1MFY24 $-45.8MFY25 $-44.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$407.3M +22.1%	$333.6M +168.1%	$124.5M +138.6%	$52.2M +416.6%	$10.1M +33.4%	$7.6M
Net Income	$-61.6M -57.4%	$-39.1M +40.8%	$-66.1M +1.7%	$-67.2M +57.5%	$-158.2M -67.7%	$-94.3M
Operating Income	$-41.0M -46.6%	$-27.9M +55.8%	$-63.3M +0.8%	$-63.8M +58.7%	$-154.3M -70.0%	$-90.8M
EPS (Diluted)	$-0.26 -52.9%	$-0.17 +43.3%	$-0.30 +28.6%	$-0.42 +72.4%	$-1.52 -44.8%	$-1.05
Total Assets	$501.6M +15.1%	$435.8M +46.4%	$297.6M +56.6%	$190.1M +26.8%	$149.9M -25.6%	$201.6M
Total Debt	$202.8M +34.5%	$150.9M +202.8%	$49.8M +86.5%	$26.7M -58.6%	$64.5M +27.1%	$50.8M
Operating Cash Flow	$-42.5M +5.2%	$-44.8M +50.1%	$-89.7M -28.1%	$-70.0M +54.1%	$-152.6M -87.3%	$-81.4M
Free Cash Flow	$-44.0M +4.0%	$-45.8M +49.1%	$-90.1M -28.5%	$-70.1M +54.6%	$-154.4M -88.9%	$-81.8M

Get alerted when ARDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ARDELYX, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARDX

BlackRock, Inc.
$119.9M23,504,630 sh
Rubric Capital Management LP
$82.6M16,202,700 sh
MILLENNIUM MANAGEMENT LLC
$70.9M13,900,773 sh
STATE STREET CORP
$68.1M13,356,128 sh
VANGUARD CAPITAL MANAGEMENT LLC
$53.4M10,471,494 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$48.7M9,546,732 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$40.9M8,026,774 sh
GEODE CAPITAL MANAGEMENT, LLC
$32.7M6,401,736 sh
Jupiter Topco LLC
$27.0M5,302,311 sh
TWO SIGMA INVESTMENTS, LP
$26.6M5,209,823 sh

Fund	Value	Shares
BlackRock, Inc.	$119.9M	23,504,630
Rubric Capital Management LP	$82.6M	16,202,700
MILLENNIUM MANAGEMENT LLC	$70.9M	13,900,773
STATE STREET CORP	$68.1M	13,356,128
VANGUARD CAPITAL MANAGEMENT LLC	$53.4M	10,471,494
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$48.7M	9,546,732
VANGUARD PORTFOLIO MANAGEMENT LLC	$40.9M	8,026,774
GEODE CAPITAL MANAGEMENT, LLC	$32.7M	6,401,736
Jupiter Topco LLC	$27.0M	5,302,311
TWO SIGMA INVESTMENTS, LP	$26.6M	5,209,823

Companies Similar to ARDX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

EOLS

Evolus, Inc.

AI score

Very similar · 8 shared holders

DIADEMA PARTNERS LP Krensavage Asset Management, LLC Stonepine Capital Management, LLC

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Very similar · 17 shared holders

Rock Springs Capital Management LP Eversept Partners, LP Krensavage Asset Management, LLC

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

AI score

Similar quality profile · 14 shared holders

SECTOR GAMMA AS Hennion & Walsh Asset Management, Inc.Raiffeisen Bank International AG

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 12 shared holders

Hennion & Walsh Asset Management, Inc.SECTOR GAMMA AS Virtus Investment Advisers, LLC

IMCR

Immunocore Holdings plc

AI score

Similar quality profile · 12 shared holders

J. Goldman & Co LP DIADEMA PARTNERS LP Hennion & Walsh Asset Management, Inc.

SUPN

SUPERNUS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 11 shared holders

Hennion & Walsh Asset Management, Inc.Krensavage Asset Management, LLC Freestone Grove Partners LP

TARS

Tarsus Pharmaceuticals, Inc.

AI score

Similar quality profile · 13 shared holders

Rock Springs Capital Management LP Eversept Partners, LP J. Goldman & Co LP

SNDX

Syndax Pharmaceuticals Inc

AI score

Similar quality profile · 13 shared holders

Eversept Partners, LP Hennion & Walsh Asset Management, Inc.SECTOR GAMMA AS

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARDX on your watchlist

Track score changes the day ARDELYX, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARDX a good stock to buy?

13F Pro's AI-powered analysis of ARDELYX, INC. (ARDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARDX are available on the ARDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARDX is classified as a small company.

Which hedge funds own ARDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARDELYX, INC.'s investment landscape.